This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zwieten, P.A. v. Search for Related Content PubMed Articles by Zwieten, P.A. v. Social Bookmarking                         What's this?

Drug Treatment of Congestive Heart Failure

Departments of Pharmacotherapy, Cardiology and Cardiothoracic Surgery, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1077 NN Amsterdam, The Netherlands G.L.vangaalen{at}amc.uva.nl

Congestive heart failure (CHF), a syndrome with several pathologic backgrounds, is associated with a series of neuroendocrine (neurohumoral) processes that are triggered by the underlying problem of cardiac pump failure. Several important pathophysiologic systems are stimulated, including the reninangiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), the release of vasopressin from the hypothalamus/pituitary axis, and the release of atrial-brain natriuretic peptides from the heart. These neuroendocrine mechanisms are not only highly relevant from diagnostic and pathophysiologic viewpoints, but are also realistic targets for drug treatment. Over the years, it has become clear that drug treatment of CHF with inotropic agents, aiming at the improvement of pump failure, offers but modest benefit. It appears to be preferable to use drugs to target the neuroendocrine processes, and this approach will be the goal of this review. Accordingly, the following therapeutic principles may be applied: 1. Suppression of the hyperactivity of the RAAS, by means of angiotensin-converting enzyme (ACE) inhibitors or angiotensin type 1-receptor antagonists (AT,-blockers); 2. Antagonism of the effects of aldosterone, by means of spironolactone and (possibly) other aldosterone antagonists; 3. Suppression of the hyperactivity of the SNS by means of f-blockers, and (possibly) centrally acting agents such as clonidine, which cause peripheral sympatho-inhibition; and 4. Vasopressin antagonists. The validity of these various concepts will be the subject of the present review.

Seminars in Cardiothoracic and Vascular Anesthesia, Vol. 7, No. 1, 13-17 (2003)
DOI: 10.1177/108925320300700103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?